SynthesisCancer reports (Hoboken, N.J.)2025
Risk Factors for the Development of Barrett's Esophagus and Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis.
Synthesis in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- E-cigarette use and Barrett's esophagus: evaluating a new risk in the era of vaping.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Assessing the Relationship Between Steatotic Liver Disease and Barrett's Esophagus: A Cross-Sectional Analysis of 5507 Screening Participants.Zeitschrift fur Gastroenterologie · 2026Article
- Pathogenesis of Barrett's Esophagus: Evolving and Emerging Mechanisms.Gastrointestinal endoscopy clinics of North America · 2026Review
- AI-Driven Risk Prediction Tool (TSP-9) Informs Risk-Aligned Care for Patients with Barrett's Esophagus.Diagnostics (Basel, Switzerland) · 2025Article
- Pterostilbene Attenuates High Fat Diet-induced Obesity and Hepatic Dysfunction in Rats: A Functional Evaluation Based on Taiwan's Health Food Assessment Criteria.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBarrett's esophagus (BE) is the most widely established precursor to esophageal adenocarcinoma (EAC). Despite current screening guidelines, more than 90% of EAC patients lack a previous diagnosis of BE. We performed a systematic review and meta-analysis to identify the most important risk factors for the development of BE or EAC. RECENT
findingsPubMed.gov, Ovid Medline, Embase, and Cochrane Library were searched through March 15, 2024. Studies comparing characteristics of patients with endoscopically diagnosed BE or EAC to control groups satisfied our inclusion criteria. Dual extraction provided data for random-effects meta-analyses. Sufficient data were extracted from 54 included studies to perform our meta-analyses. There were five risk factors with significant associations for the development of BE: symptoms of gastroesophageal reflux at least once weekly (OR, 3.56; 95% confidence interval [CI], 2.03-6.25; p = 0.004) tobacco smoking (OR, 1.41; 95% CI, 1.30-1.51; p < 0.001); alcohol use (OR, 1.37; 95% CI, 1.10-1.71; p = 0.008); male gender (OR, 1.36; 95% CI, 1.19-1.57; p < 0.001); and obesity (BMI > 30 kg/m
conclusionFive risk factors showed significant associations with the development of BE and one with the development of EAC, with over a three-fold increase in BE for patients with gastroesophageal reflux more than once weekly. These data could prove useful in developing diagnostic paradigms with higher emphasis on patients experiencing more frequent acid reflux.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.